Gateway Investment Advisers’s West Pharmaceutical WST Stock Holding History

Gateway Investment Advisers’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$699K	Buy	1,946 +538	+38%	+$164K	0.01%	515
2026 Q1	$353K	Buy	+1,408	New	+$350K	﹤0.01%	576
2025 Q3	–	Sell	-21,661	Closed	-$4.74M	–	542
2025 Q2	$4.74M	Sell	21,661 -27,882	-56%	-$5.96M	0.05%	200
2025 Q1	$11.1M	Buy	+49,543	New	+$13.7M	0.13%	127
2024 Q4	–	Sell	-1,736	Closed	-$521K	–	525
2024 Q3	$521K	Buy	1,736 +76	+5%	+$23.3K	0.01%	383
2024 Q2	$547K	Buy	1,660 +153	+10%	+$54.1K	0.01%	374
2024 Q1	$596K	Buy	+1,507	New	+$557K	0.01%	377
2021 Q1	–	Sell	-49,426	Closed	-$14M	–	540
2020 Q4	$14M	Sell	49,426 -9,283	-16%	-$2.6M	0.15%	130
2020 Q3	$16.1M	Buy	58,709 +32,657	+125%	+$8.64M	0.19%	113
2020 Q2	$5.92M	Buy	+26,052	New	+$5.12M	0.07%	211

Other funds holding WST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Gateway Investment Advisers's WST Position: Q2 2026 in Review

Gateway Investment Advisers increased its West Pharmaceutical (WST) stake by 38% in Q2 2026, buying an estimated $164K and bringing the position to 1,946 shares worth $699K. The position accounts for 0.01% of the portfolio, ranked #515.

Gateway Investment Advisers first reported a position in WST in Q2 2020 and has held it in 10 quarters since. The position peaked at $16.1M in Q3 2020. 834 funds tracked by Wall St. Rank hold WST as of Q2 2026.

Gateway Investment Advisers held 1,946 shares of West Pharmaceutical worth $699K as of Q2 2026.
Gateway Investment Advisers bought 538 West Pharmaceutical shares in Q2 2026, an estimated $164K.
West Pharmaceutical made up 0.01% of Gateway Investment Advisers's portfolio in Q2 2026, its #515 holding.
Gateway Investment Advisers first reported a position in West Pharmaceutical in Q2 2020 and has held it in 10 quarters since.
Gateway Investment Advisers's West Pharmaceutical position peaked at $16.1M in Q3 2020.
834 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Gateway Investment Advisers's 13F filing for Q2 2026, filed 20 Jul 2026.